Background
==========

Several intervention studies in humans and animals suggest that consumption of soy and isoflavone-rich soy protein may decrease body weight \[[@B1],[@B2]\]. Postmenopausal women with relatively high isoflavone consumption in their normal diet showed an inverse association with obesity in a cross-sectional study \[[@B3]\]. However, the protein content of soy may be at least partly responsible for the observed effects, and the contribution of soy isoflavones such as genistein and daidzein remains uncertain \[[@B4],[@B5]\]. There is some evidence that may link isolated isoflavone consumption *per se*to the regulation of body weight. Soy isoflavones show functional and structural similarities to estradiol \[[@B6]\], mainly by binding to the estrogen receptor β \[[@B7]\]. In ovariectomized mice, loss of circulating estrogen increases body weight and fat mass, and this is reversed by estrogen replacement \[[@B8],[@B9]\]. Similar effects have been observed in ovariectomized mice treated with oral genistein \[[@B10],[@B11]\]. Even though the role of postmenopausal hormone replacement in modulating body weight is controversial \[[@B12],[@B13]\], some studies indicate that the activation of the estrogen receptor interferes with the regulation of gut hormones commonly thought to be involved in the regulation of food intake. Food intake decreases during the high estrogen period in the estrous cycle in rats, and estradiol replacement in ovariectomized rats increased the satiating effect of the gut hormone cholecystokinin \[[@B14]\]. Estrogen replacement in hysterectomized postmenopausal women also increased peripheral concentrations of the orexigenic gut hormone ghrelin \[[@B15]\]. Peptide YY (PYY), a member of the neuropeptide Y (NPY) family and another gut derived \"satiety hormone\", is assumed to have potent anorexigenic properties, with potential therapeutic use in obese humans \[[@B16]\]. Human PYY has been shown to be regulated in a gender specific manner, with higher PYY secretion in females than in males \[[@B17]\]. Treatment of ovariectomized rodents with estradiol increases the number of receptors of several neuropeptides, including NPY receptors in the brain \[[@B18]\]. To date, potential effects of isolated isoflavones on PYY have not been reported, and only one study investigated effects of isolated isoflavones on total ghrelin concentrations \[[@B19]\]. In addition, no long-term randomized controlled studies have investigated whether changes in PYY concentrations influence food intake in free living humans. The hypothesis of the present study was that estradiol-like properties of isolated isoflavones may influence PYY and ghrelin, and thus energy intake and body weight.

Results
=======

Results of biomarkers are given as postabsorptive concentrations, measured after a standardized low-fat evening meal and after 12 h overnight fasts. P values for PYY, glucose, insulin and ghrelin are given for the treatment effect within a linear mixed model. Differences from baseline were used as response variable after adjustment for changes in BMI.

Dietary intake and body weight
------------------------------

Dietary intake was assessed at baseline and after four weeks of each intervention arm. Macronutrient intake at baseline was 15% of energy as protein, 34% as fat, and 47% as carbohydrate. Even though participants were instructed to replace snacks by the cereal bars, body weight increased moderately, but significantly, during both intervention periods (placebo + 0.66 ± 0.87 kg, (P = 0.018); isoflavones + 0.40 ± 0.94 kg, (P \< 0.001)). There was no significant difference in body weight and body mass index (P \> 0.331) between treatments (table [1](#T1){ref-type="table"}). There were no significant differences in energy intake or macronutrient intake, both across the treatments and compared to baseline (wk4 - wk0; interaction treatment vs. time, P = 0.634).

###### 

Plasma PYY, body weight, and urinary isoflavone concentrations in postmenopausal women, at baseline (t0) and after 8 weeks (t8) of isoflavone or placebo consumption (n = 34)

                           **Isoflavones**   **Placebo**   **P value^1^**                
  ------------------------ ----------------- ------------- ---------------- ------------ -------
  Total PYY (pmol/L)       51 ± 2            55 ± 2        52 ± 3           50 ± 2       0.010
  BMI (kg/m^2^)            24.5 ± 2.7        24.6 ± 2.7    24.5 ± 2.8       24.7 ± 2.8   0.331
  Glucose (mmol/L)         5.7 ± 0.1         5.6 ± 0.1     5.7 ± 0.1        5.6 ± 0.1    0.641
  Insulin (pmol/L)         37 ± 3            39 ± 3        38 ± 3           34 ± 3       0.231
  Total ghrelin (pmol/L)   129 ± 12          131 ± 12      133 ± 13         123 ± 11     0.297

Data are given as mean ± SEM except for BMI which is presented as mean ± SD. BMI = body mass index.

^1^P values are shown for the treatment effect within a linear mixed model. Differences from baseline were used as response variable after adjustment for changes in BMI.

Effect of isoflavone consumption on PYY
---------------------------------------

During isoflavone consumption, PYY concentrations increased by eight percent, and during placebo consumption, PYY concentrations decreased by four percent (P = 0.010 for treatment differences) (table [1](#T1){ref-type="table"}).

Changes in PYY levels were independent of changes in BMI, and were negatively correlated with baseline PYY (r = -0.67; P \< 0.001). PYY concentrations were not significantly different between equol producers and equol non-producers.

Effect of isoflavone consumption on ghrelin
-------------------------------------------

At baseline, ghrelin was significantly lower in equol producers (110 ± 16 pmol/L) than in equol non-producers (162 ± 17 pmol/L); (P = 0.025), independent of BMI. However, isoflavone treatment did not affect ghrelin concentrations (table [1](#T1){ref-type="table"}).

Other parameters
----------------

During isoflavone treatment, urinary genistein and daidzein excretion increased 15 fold and 24 fold, respectively. There was no significant increase in urinary genistein and daidzein concentrations following placebo treatment. According to the cut-offs used in the present study \[[@B20]\], 50 percent of the participants (n = 17) were classified as equol producers. Equol production increased 35 fold in equol producers during the active treatment, compared to an 1.7 fold increase in equol non-producers (table [2](#T2){ref-type="table"}).

###### 

Urinary isoflavone concentrations in postmenopausal women at baseline (t0) and week 8 (t8) of isoflavone and placebo arms (n = 34)

                                  **Isoflavones**   **Placebo**   ***P*value^1^**              
  ------------------------------- ----------------- ------------- ----------------- ---------- ---------
  Genistein (nmol/L)              808 ± 134         12266 ± 852   655 ± 68          647 ± 73   \<0.001
  Daidzein (nmol/L)               334 ± 88          8146 ± 651    315 ± 82          223 ± 40   \<0.001
  Equol, (nmol/L)                 154 ± 12          3040 ± 713    162 ± 15          198 ± 23   \<0.001
   Equol producers (n = 17)       164 ± 11          5834 ± 749    179 ± 16          237 ± 29   \<0.001
   Equol non-producers (n = 17)   143 ± 14          245 ± 16      145 ± 13          160 ± 12   \<0.001

Data are given as mean ± SEM.

^1^P values are shown for the treatment effect within a linear mixed model. Differences from baseline were used as response variable.

Plasma glucose and insulin were unaffected by isoflavone treatment (table [1](#T1){ref-type="table"}).

Power analysis
--------------

A between-treatment difference in body weight \> 500 g after 8 weeks intervention was assumed to be relevant. The estimated power of this study was 94 percent to detect a difference of 500 ± 900 g in body weight between treatments with a sample size of 34 subjects and a significance level of 0.05.

Discussion
==========

Consumption of soy derived food rich in isoflavones has been suggested to have favorable effects on energy intake and body weight \[[@B5]\]. However, soy derived food is also rich in protein, and an increased protein intake might be responsible for the observed effects. The potential contribution of isolated isoflavones to the regulation of energy and body weight remains uncertain. In the present study, isoflavone treatment for eight weeks did not significantly influence energy intake, macronutrient intake, or body weight, both across the treatments or compared to baseline. Isoflavone treatment did not affect preprandial ghrelin, which seems to be in contrast to results of a previous study that investigated effects of isoflavone treatment on ghrelin concentrations \[[@B19]\]. However, the observed differences in the mentioned study are mainly due to increased ghrelin concentrations in the placebo group rather than altered ghrelin concentrations after isoflavone intake. In addition, high within and between subject variations in preprandial ghrelin concentrations have been reported, which may lead to the detection of random effects rather than of true treatment effects \[[@B21]\]. Despite unchanged ghrelin concentrations during isoflavone treatment in the present study, the ability of producing equol, a gut bacterial metabolite of daidzein with higher binding affinity to estrogen receptors compared with its precursor \[[@B22]\], was associated with lower ghrelin concentrations at baseline. The capability to produce equol is greatly varying between individuals, with about 30--40% equol producers in the Western population \[[@B22]\]. It is speculated that equol producers may have an increased benefit from soy consumption \[[@B20],[@B23]\]. However, even though the ability of producing equol was associated with lower ghrelin concentrations at baseline, ghrelin responses remained unaffected during isoflavone treatment in the present study. This indicates that equol may have a long-term suppressive effect on ghrelin concentrations, which probably will not respond to further and relatively short-term increases of equol concentrations. In contrast to unchanged ghrelin in the present study, isolated soy isoflavones significantly increased plasma PYY concentrations. Given the assumed potent anorexigenic properties of PYY \[[@B16]\], our data do not suggest a major role of PYY on the regulation of body weight. Notably, power analysis indicated that even a moderate difference in body weight between treatments was highly likely to be detected. Only moderate effects of PYY on the regulation of body weight may contribute to the explanation of controversial findings in the literature. In humans, short-term intravenous administration of PYY \[3-36\] in supraphysiological \[[@B24],[@B25]\], but not in physiological doses \[[@B25]\] reduces appetite and food intake. Long-term studies in humans are not available to date. A two weeks continous PYY infusion in colectomized rats did not affect food intake and body weight \[[@B26]\], and data obtained from other animal studies are controversially discussed \[[@B27]\]. The duration of the present study may have been too short to detect relevant differences in body weight. However, most studies linking physiological ghrelin and PYY responses to food intake investigated the effects of only one meal. A relatively small but well performed study over 16 weeks did not show an effect of macronutrient intake and energy intake on preprandial ghrelin \[[@B21]\]. It needs, however, to be emphasized that food diaries, and not weighed food intake were used to assess energy intake in the present study, and a more rigorous appetite experiment might detect smaller effects. In addition, adaptation processes and counter regulatory responses in other satiety hormones than total ghrelin, such as acylated ghrelin, glucagon-like peptide (GLP-1), or cholecystokinin may have masked detectable differences in energy intake or body weight.

Conclusion
==========

Isoflavone treatment had no effect on energy intake and body weight, despite significantly increased preprandial PYY concentrations. The findings indicate that PYY is not a major factor in the regulation of body weight. Preprandial ghrelin was not affected by isoflavone consumption. The isoflavone contents are not likely to explain the observed beneficial effects of soy consumption on energy intake and body weight.

Methods
=======

Subjects
--------

This study was part of a multi-center intervention located in Frederiksberg (Denmark), Reading (UK), Rome (Italy), and Potsdam (Germany). Potential effects of isoflavones on gut satiety hormones and body weight were investigated in the German population. Thirty-six healthy postmenopausal women (age 59 ± 6 y, BMI 24.7 ± 2.8 kg/m^2^), defined as at least 12 months since the last menstrual cycle, were recruited by advertisement in the local media. Thirty-four of the subjects completed the intervention. One of the subjects was excluded because of a prolonged respiratory infection, the other one because of start of a treatment with an angiotensin-converting-enzyme inhibitor. None of the volunteers had used hormone replacement therapy for six months, antibiotics for three months, or isoflavone, vitamin, or mineral containing supplements for two months. All volunteers were non-smokers. Parameters of renal and liver function were within normal range. Subjects were classified as equol producers, when equol in a 24 h urine sample exceeded 936 nmol/liter during isoflavone treatment, which corresponds to an urinary equol excretion of \> 0.45 mg/day \[[@B20]\]. The study protocol was approved by the Ethics Committee of the University of Potsdam, Germany. All volunteers gave written informed consent prior to the study.

Study design
------------

This was a randomized, double-blind, placebo-controlled, 2 × 8-wk crossover study, separated by an 8-wk washout period. Subjects were invited to the metabolic unit on 6 occasions (t0, t4, and t8 on each intervention arm), after 12-h overnight fasts. To exclude potential second-meal effects, a set low-fat evening meal (\< 10 g fat) was consumed the evening before each of the study days. Recipes for the preparation of the meals were provided to the participants. Energy contents of the meals were comparable. Subjects were asked to consume two fruit cereal bars/d (Health & Diet Food, Manchester, UK), one in the morning and one in the afternoon, in addition to their normal diet. During the treatment period, cereal bars were enriched with 2 × 25 mg isoflavones/d, with a genistein to daidzein ratio of 2:1 (\"Solgen 40\", Solbar Plant Extracts, Ashdod, Israel). Thus, isoflavone intake in the treatment group of the present study was in the upper range of the daily isoflavone intake in traditional Asian diets (15 -- 50 mg/d) \[[@B28]\]. The product was tested before packaging and during the study by HPLC, to ensure stability of the isoflavones \[[@B29]\]. Placebo did not contain any isoflavones. Each cereal bar (40 g) had an average nutrient content of energy (652 kJ); protein 2.6 g; carbohydrate 17.3 g; fat 8.5 g; fiber 1.8 g; sodium 0.012 g. Subjects perceived the isoflavone-enriched and placebo cereal bars as identical in taste and visual appearance. Habitual diet was assessed by estimated 3-d food records three times during the study. Diet diaries were completed at baseline (t0) and after 4 weeks (t4) of each intervention arm. All food records included two week days and one weekend day. Nutrient intake was calculated based on the German Food and Nutrient Data Base Bundeslebensmittelschlüssel BLS II.3 \[[@B30]\]. To avoid weight gain, subjects were advised to replace snacks with the cereal bars. Subjects kept daily records of cereal bar consumption and well-being in a study diary. Dietary compliance was further assessed by measurement of phytoestrogen concentrations in 24-hour urine \[[@B31]\], which was collected at start and end of each intervention period. Body weight was measured at each visit.

Biochemical parameters
----------------------

Blood was collected in ice-chilled EDTA tubes for the analysis of glucose, ghrelin, and PYY. Following centrifugation at 1600 g for 10 minutes at 4°C, aliquots were immediately frozen at -20°C until assayed. All samples from individual subjects were measured in the same assay. Immunoreactive total ghrelin was measured by a commercially available radioimmunoassay (Phoenix Pharmaceuticals, Mountain View, CA, USA), as previously described \[[@B32]\]. Immunoreactive total human PYY was measured by a commercially available radioimmunoassay (LINCO Research, Missouri, USA), using^125^I-labeled bioactive PYY as tracer and a PYY antiserum to determine the level of active PYY by the double antibody/PEG technique. The PYY antibody is raised in guinea pigs and recognizes both the PYY 1--36 and PYY 3--36 forms of human PYY. Intra- and inter-assay coefficient of variation was 5.3% and 7.0%, respectively. Insulin, and glucose, and urinary phytoestrogens (genistein, daidzein, equol) were analyzed as previously described \[[@B33]\].

Statistical analyses
--------------------

Data are given as mean ± SEM, anthropometric data are given as mean ± SD. Changes from baseline, e.g. week-8 compared to week-0 (t8-t0), were used as the dependent variables. Data were calculated as changes from baseline on the original scale, when normally distributed. Skewed data where log transformed, and changes from baseline on the log scale were calculated, and these changes now correspond to a multiplicative change from baseline on the original scale. Subjects were included as a random factor within a linear mixed model. Fixed effects included in the final model were: baseline parameters, treatment, treatment order, and changes in BMI. Further exploratory investigation of equol group was included in the model. Pearson\'s correlation coefficient was calculated between baseline PYY and changes in PYY. Statistical analysis was performed using SAS 8.4 (SAS Institute Inc., Cary, NC).

Abbreviations
=============

BMI: body mass index; PYY: peptide YY.
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